3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Hematopoietic and Lymphatic System Neoplasm
8
Malignant Solid Neoplasm
7
Solid Tumor
2
Hematopoietic and Lymphoid System Neoplasm
2
Advanced Malignant Solid Neoplasm
2
Stomach Neoplasms
1
Solid Tumors
1
Sarcoma
1
Rhabdomyosarcoma
1
Retinoblastoma
1
Rectal Neoplasms
1
Pelvic Neoplasms
1
Ovarian Neoplasms
1
Mesothelioma, Malignant
1
Malignant Female Reproductive System Neoplasm
1
Liposarcoma
1
Fallopian Tube Neoplasms
1
Desmoplastic Small Round Cell Tumor
1
Colonic Neoplasms
1
Chemotherapy-Induced Peripheral Neuropathy
1
Advanced Rare Malignant Solid Neoplasm
1
Interventions
Cisplatin
57
Pemetrexed
46
pembrolizumab
18
Nivolumab
15
Carboplatin
15
Gemcitabine
14
Cyclophosphamide
13
Radiotherapy
10
Drug Therapy
9
atezolizumab
8
Platinum
7
Ipilimumab
7
Doxorubicin
7
durvalumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
tremelimumab
5
sodium thiosulfate
5
Vinorelbine
5
Radiotherapy, Intensity-Modulated
5
Interleukin-2
5
Chemotherapy, Adjuvant
5
Cerebral Decortication
5
sargramostim
4
fludarabine
4
defactinib
4
aldesleukin
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
cediranib
3
Photochemotherapy
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Specimen Handling
×
Other solid neoplasm
×
Clear all
NCT04213794
2025-02-20
TOASTIT
Mayo Clinic
Phase EARLY_PHASE1
Terminated
2 enrolled